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16 Pharmaceutical Compounds in Estuarine and Coastal Waters
John L. Zhou and Zulin Zhang
16.1 IntroductIon
Pharmaceuticals and personal care products (PPCPs) are a group of emerging contaminants of 
environmental concern that have remained largely unrecognized as such until recent advances in 
trace-level analytical measurements (Cha et al., 2006; Erickson, 2002; Gros et al., 2006; Lindsey 
et al., 2001). There is growing concern over the occurrence and fate of PPCPs in the environment, 
with evidence of adverse effects in terrestrial and aquatic organisms, and also the potential of some 
antibiotics to induce resistance in naturally occurring bacterial strains (Hirsch et al., 1998).
Over three thousand chemical substances are used in human and veterinary medicine (Ternes 
et al., 2004). Such pharmaceuticals include antiphlogistics/anti-inflammatory drugs, contracep-
tives, β-blockers, lipid regulators, tranquilizers, antiepileptics, and antibiotics (Ternes et al., 2004; 
Petrovic et al., 2005). Some typical pharmaceuticals classified by groups according to therapeutical 
effect and physicochemical properties are listed in Table 16.1. During and after treatment, humans 
and animals excrete a combination of intact and metabolized pharmaceuticals, many of which are 
generally soluble in water and have been discharged to the aquatic environment with little evalua-
tion of possible risks or consequences to humans and the environment. In addition, chemicals that 
are components of personal care products number in the thousands, and are contained in skin care 
products, dental care products, soaps, sunscreen agents, and hair care products. Annual production 
exceeds 1 × 106 tonnes worldwide (e.g., >553,000 tonnes was produced in Germany alone in 1993; 
Daughton and Ternes, 1999). Included in this category are fragrances (e.g., nitro and polycyclic 
musks), UV blockers (e.g., methylbenzylidene camphor), and preservatives (e.g., parabens). Unlike 
pharmaceuticals, personal care products enter wastewater and the aquatic environment after regular 
use during showering or bathing. The environmental fates and effects of many cosmetic ingredients 
are poorly known, although considerable persistence and bioaccumulation in aquatic organisms 
have been reported (Daughton and Ternes, 1999; Kallenborn et al., 2001).
In many aquatic environments, particularly in North America and Europe, pharmaceuticals, 
hormones, metabolites, biocides, musks, and flame retardants have been measured (Ternes, 1998; 
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Kolpin et al., 2002; Hirsch et al., 1999; Hilton and Thomas, 2003). One of the principal sources is 
through the release of municipal wastewater. Some pharmaceuticals do not readily biodegrade in a 
marine environment, and have been detected in seawater (Weigel et al., 2002; Thomas and Hilton, 
2004) and sediments (Samuelsen et al., 1992). Weigel et al. (2002) reported a wide distribution of 
clorfibric acid, caffeine, and N,N-diethyl-3-toluamide (DEET, an insect repellent) in concentra-
tions up to 19, 16, and 1.1 ng L–1, respectively, throughout the North Sea, off Scotland, the outer 
and inner German Bight, as well as the Danish and Norwegian coasts. Samples collected from UK 
table 16.1
Pharmaceuticals and their Physicochemical Properties
compound therapeutic class logKow pKa MW Formula
Ketoprofen Analgesic/anti-inflammatories 3.12 4.45 254 C16H14O3
Naproxen 3.18 4.15 230 C14H14O3
Ibuprofen 3.97 4.91 206 C13H18O2
Indomethacine 4.27 4.5 358 C19H16ClNO2
Diclofenac 4.51 4.14 296 C14H10Cl2NO2
Meclofenamic acid 5.12 4.2 241 C15H15NO2
Acetaminophen 0.46 9.38 151 C8H9NO2
Propyphenazone Lipid regulators/cholesterol- 
lowering statin drugs
1.94 n/a 230 C14H18N2O
Clofibric acid n/a n/a 214 C10H11O3Cl
Gemfibrozil 4.77 n/a 250 C15H22O3
Bezafibrate 4.25 n/a 362 C19H20ClNO4
Pravastatin 3.1 n/a 446 C23H36O7
Mevastatin 3.95 n/a 391 C25H38O5
Carbamazepine Psychiatric drugs 2.47 7 236 C15H12NO
Fluoxetine 3.82 8.7 309 C17H18F3NO
Paroxetine 3.95 n/a 329 C19H20FNO3
Lansoprazole Antiulcer agent 2.58 8.73 369 C16H14F3N3O2S
Loratadine Histamine H1 and H2 receptor 
antagonists
5.20 n/a 383 C22H23ClN2O2
Famotidine –0.64 n/a 337 C8H15N7O2S3
Ranitidine 0.27 n/a 314 C13H22N4O3S
Erythromycin Antibiotics 3.06 8.8 734 C37H67NO13
Azythromycin 4.02 8.74 749 C38H72N2O12
Sulfamethoxazole 0.89 6.0 253 C10H11N3O3S
Trimethoprim 0.91 7.12 290 C14H18N4O3
Ofloxacin n/a n/a 361 C18H20FN3O4
Atenolol β-Blockers 0.16 9.6 266 C14H22N2O3
Sotalol 0.24 n/a 272 C12H20N2O3S
Metoprolol 1.88 9.68 267 C15H25NO3
Propranolol 1.2–3.48 9.5 260 C16H21NO2
Meberverine Gastrointestinal n/a n/a 429 C25H35O5
Thioridazine Antidepressant n/a n/a 371 C21H26N2S2
Tamoxifen Anticancer n/a n/a 372 C26H29NO
Monensin Growth promoters 2.75–3.89 6.65 692 C36H61NaO11
Note: logKow, log of the octanol-water partition coefficient; pKa, log of the ionization constant; MW, molecular weight; n/a, 
not available.
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estuaries had clorfibric acid concentrations of approximately 100 ng L–1 in two samples (Thomas 
and Hilton, 2004). Other frequently measured pharmaceutical compounds found in UK estuaries 
included clotrimazole (a topical antifungal agent, in 59% of samples, up to 22 ng L–1), ibuprofen (an 
analgestic, in 50% of samples, up to 569 ng L–1), and propranolol (an antihypertensive drug, in 41% 
of samples, up to 56 ng L–1), with several other drugs appearing in approximately one-third of the 
samples at lower concentrations (Thomas and Hilton, 2004).
The concentrations of pharmaceuticals present in the aquatic environment are generally in the 
sub ng L–1 range and do not necessarily represent a major threat to drinking water quality. The con-
sequence of a continuous presence of low concentrations of pharmaceuticals for ecosystems is still 
not fully understood. A discussion of various aspects of ecotoxicology of pharmaceuticals in the 
environment can be found in recent reviews (Cunningham et al., 2006; Fent et al., 2006; Crane et al., 
2006; Hernando et al., 2006). It is quite clear that environmental risk assessment must be based 
on reliable data about the actual concentrations of pharmaceuticals in aquatic systems. Therefore, 
efficient analytical methods are of major importance.
Fast progress in the development of analytical procedures for residue analysis of pharma-
ceutical drugs has been facilitated by the existence of considerable expertise in other micro-
organic pollutants residue analysis. Strategies successfully used for routine analysis of traces 
of some polar organic contaminants have been modified and subsequently applied to residue 
analysis of pharmaceuticals. In many cases, the common procedures involve sampling, sam-
ple treatment (e.g., preconcentration, cleanup step) by solid-phase extraction (SPE) or related 
techniques, followed by analysis using chromatography in combination with mass spectrometry 
(MS) as detector. When residue analysis of pharmaceuticals became an important issue in the 
1990s, gas chromatography (GC) was the preferred chromatographic technique together with 
various derivatization procedures for the analytes. Nowadays, GC-MS may still be the perfect 
technique for certain classes of pharmaceuticals (Togola and Budzinski, 2008), although high- 
performance liquid chromatography (HPLC) hyphenated with atmospheric pressure ioniza-
tion–MS has established itself as a better choice for simultaneous determination of pharma-
ceuticals of widely differing structures (Buchberger, 2007). In this chapter, the analysis of 
pharmaceuticals in estuarine and coastal waters will be discussed, including the sampling, pre-
concentration, and instrumental measurement.
16.2 saMPlIng
The first task in any analysis is sampling. The sample being taken should be representative, the 
composition of which is as close as possible to the whole mass of whatever (e.g., estuarine water) 
is being analyzed. Obtaining a good sample is a crucial first step in the chemical analysis process. 
Prior to sampling, a sampling strategy should be drawn concerning the locations of sampling, the 
number of samples to be taken, where to conduct replicate sampling, size of samples, and storage 
and transport of samples (see Chapter 1). Preparation should also ensure that all the in situ measure-
ment equipment is calibrated, and necessary sampling tools and containers are cleaned appropri-
ately before sampling.
There are two sampling methods, spot and passive sampling, which are complementary to each 
other. Currently, the most widely used technique for performing monitoring of organic contami-
nants is spot sampling followed by laboratory-based extraction and analysis. In general, spot sam-
pling uses a glass sampler or stainless steel sampler such as buckets (Gulkowska et al., 2007), some 
of which can be opened underwater to prevent the sampling of the surface microlayer (Zhou et al., 
1996). The sample volume is typically 1–2 L (Gulkowska et al., 2007; Roberts and Thomas, 2006), 
although for seawater samples this may be increased to 10–100 L. General biocides such as sodium 
azide (final concentration of 0.02 M) are added to each sample on site to inactivate bacteria and 
prevent sample degradation during storage and processing. The samples are stored in a refrigera-
tor below 4°C until filtration and extraction. Prior to use, all glassware is thoroughly soaked with 
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detergents (e.g., Decon-90) and cleaned with ultrapure water, before further treatment (e.g., rinsed 
with distilled solvents such as dichloromethane and methanol, or baked in a furnace). The procedure 
should be adjusted for the compounds to be analyzed, based on their physicochemical properties 
(e.g., solubility, polarity).
Spot sampling is a well-established technique that is easy to perform and inexpensive, and 
requires limited expertise. However, it only yields an instantaneous measurement of pollut-
ant levels and suffers from the uncertainty of short- and long-term concentration variations, 
which occur in the aquatic environment. An increase in sampling frequency or the use of flow- 
and time-weighted automatic samplers may reduce such uncertainty; however, the associated 
increase in costs can be prohibitive. There has been rapid development in the use of passive sam-
pling devices such as polar organic chemical integrative sampler (POCIS) (Alvarez et al., 2004), 
Chemcatcher (Mills et al., 2007), and silicon rod (Paschke et al., 2007) that allow continuous 
monitoring of aqueous pollutants, with the disadvantage of using organisms (passive sampler 
could mimic the bioconcentration of pollutants in aquatic organisms but not suffer from adverse 
effects as organisms). Of the various passive sampling devices, the most widely used is POCIS, 
which comprises a solid receiving phase (sorbent) sandwiched between two microporous poly-
ethersulfone (PES) membranes (Figure 16.1a; Zhang et al., 2008). POCIS samples from water 
and thereby enables the chemical concentration to be estimated as follows (Alvarez et al., 2004; 
Vrana et al., 2005):
 Ms = CwRst (16.1)
where Ms is the mass of analytes in the receiving phase at time t, and Cw represents time-weighted 
average concentration in water during the deployment period. Rs is the sampling rate of the system, 
which may be interpreted as the volume of water cleared of analyte per unit of exposure time by the 
device (Vrana et al., 2006; Zhang et al., 2008). Although little has been reported on the application 
of POCIS for pharmaceutical residue measurements in seawater, it has been successfully applied 
in surface and estuarine water (Jones-Lepp et al., 2004; Petty et al., 2004; Togola and Budzinski, 
2007). Figure 16.1b and c shows the operating process for applying POCIS to pharmaceutical moni-
toring in river and estuarine waters (Zhang et al., 2008).
The POCIS is versatile, and by changing the sequestrating medium, specific chemicals or chemi-
cal classes can be targeted. It is common to have POCIS of several different configurations deployed 
together to maximize the data obtained. There are two configurations of POCIS that are typically 
used. One is a generic system that is useful for general hydrophilic organic contaminant purposes, 
and the other is for pharmaceutical sampling. The generic configuration contains the triphasic sor-
bent admixture of Isolute ENV+ polystyrene divinylbenzene (Argonaut Technologies, Redwood City, 
California) and Ambersorb 1500 carbon (Rohm and Haas, Philadelphia, Pennsylvania) dispersed 
on S-X3 Biobeads (200-400 mesh, Bio-Rad, Hercules, California). This mixture exhibits excellent 
trapping and recovery of many pesticides, natural and synthetic hormones, and other wastewater-
related contaminants (Alvarez et al., 2004, 2005). The pharmaceutical configuration uses the Oasis 
HLB sorbent (Waters, Milford, Massachusetts) for sequestering the chemicals of interest. This con-
figuration is necessary, as many pharmaceuticals, with multiple functional groups, have a tendency 
to strongly bind to the carbonaceous component of the sorbent admixture. The membrane acts as a 
semipermeable barrier, allowing chemicals of interest to pass through to the sorbent, while exclud-
ing particulate matter, biogenic material, and other large, potentially interfering substances. The 
polyethersulfone membrane (Pall Gelman Sciences, Ann Arbor, Michigan) contains water-filled 
pores, 0.1 µm in diameter, to facilitate transport of the hydrophilic chemicals. The POCIS was 
designed to mimic respiratory exposure of aquatic organisms to dissolved chemicals without the 
inherent problems of metabolism, depuration of chemicals, avoidance of contaminated areas, and 
mortalities of test organisms. Also, dietary uptake of polar organic compounds likely represents 
only a small fraction of residues accumulated in aquatic organism tissues (Huckins et al., 1997). 
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FIgure 16.1 The POCIS device and its application to pharmaceutical analysis in river and estuarine waters. 
(a) Component parts of a POCIS, (b) assembled sampling device, and (c) use of sampler device in river and 
estuarine waters.
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FIgure 16.2 Comparison of the mean contaminant concentrations between spot water sampling and those 
predicted by POCIS in (a) upstream, (b) downstream, and (c) effluent outfall, Ouse Estuary, West Sussex, UK. 
BPA, bisphenol A; E1, estrone; E2, 17β-estradiol; Pro, Propranolol, Sul, sulfamethoxazole; Carb, carbam-
azepine; Indo, indomethacine; Diclo: diclofenac.
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Thus, the POCIS provides a worst-case exposure scenario for aquatic organisms, enables a con-
centration of sufficient amounts of bioavailable hydrophilic organic chemicals for some biomarker 
tests, and permits determination of the biologically relevant time-weighted average concentrations 
in water.
The POCIS devices can be deployed at the sampling site for a duration ranging from 1 week to 
2 months (Alvarez et al., 2005; Zhang et al., 2008). Quality control is achieved using both fabrica-
tion and field blanks (n = 3) for each analytical technique. Fabrication blanks account for any back-
ground contribution due to interferences from POCIS components and for contamination incurred 
during laboratory storage, processing, and analytical procedures. Field blank POCISs are used as 
quality control (QC) samples for transport, deployment, and retrieval procedures (note that these 
POCIS blanks are sealed again in the same shipping cans and stored frozen during the exposure 
period). The field blank POCISs are treated identically as the deployed devices, with the exception 
that they are not exposed to waters at the monitoring sites.
The procedures for the recovery of sequestered chemical residues from the deployed POCIS are 
as follows: Briefly, the POCISs are disassembled and the sorbent transferred into glass gravity–flow 
chromatography columns or glass beakers (Alvarez et al., 2005; Zhang et al., 2008). Chemical resi-
dues are recovered from the sorbent by organic solvent elution/extraction. Methanol is widely used 
to recover the pharmaceuticals. The extracts are reduced in volume by rotary evaporation and under 
a gentle stream of nitrogen, and then are ready for further instrumental analysis.
Zhang et al. (2008) has described the use of POCIS for analysis of emerging contaminants, 
including pharmaceuticals, and compared the predicted compound concentrations in water with 
those measured by spot sampling. As shown in Figure 16.2, for the pharmaceuticals propranolol, 
sulfamethoxazole, carbamazepine, indomethacine, and diclofenac, their mean aqueous concentra-
tions measured by spot sampling varied: 3.0–45.6 ng L–1, <LOD–17.6 ng L–1, 16.6–539 ng L–1, 
0.4–7.2 ng L–1, and 2.4–65.2 ng L–1, respectively. Their concentrations predicted by POCIS were 
2.8–40.5 ng L–1, <LOD–18.2 ng L–1, 26.3–427 ng L–1, 0.5–11.9 ng L–1, and 4.4–165 ng L–1, respec-
tively. It is apparent that for most samples, the predicted pharmaceutical concentrations by POCIS 
are similar to those by spot sampling. In addition, POCIS was validated and deployed for monitor-
ing pharmaceuticals in estuarine systems (Togola and Budzinski, 2007), confirming the potential 
application of passive samplers for routine monitoring of seawater quality.
16.3 saMPle PreParatIon
The sample preparation is an important step in analysis, particularly since the concentration levels 
of pharmaceuticals found in environmental water samples are generally too low to allow a direct 
injection into a chromatographic system. Therefore, efficient preconcentration steps are necessary 
that should also result in some sample cleanup. Several techniques have been developed and opti-
mized, with solid-phase extraction (SPE) being the most frequent. Also, solid-phase microextrac-
tion (SPME), liquid-phase microextraction (LPME), and lyophilization have been applied (Fatta 
et al., 2007). In a review of thirty-two pharmaceutical studies, Fatta et al. (2007) found that most 
(twenty-eight studies) used SPE for extraction from water samples. This extraction procedure can be 
based on multiple equilibria between the liquid phase and the sorbent in SPE cartridges.
Pharmaceuticals of adequate hydrophobicity can easily be preconcentrated using any reversed-
phase material such as alkyl-modified silica or polymer-based materials (Buchberger, 2007). 
Deprotonation of acidic compounds and protonation of basic compounds should be suppressed 
to ensure sufficient hydrophobicity of the analytes. Therefore, acidic pharmaceuticals should be 
preconcentrated under acidic conditions, whereas basic analytes should be preconcentrated at 
an alkaline pH range. Alternatively, mixed-mode SPE materials can be used that exhibit both 
reversed-phase and cation exchange properties due to the presence of sulfonic acid groups on the 
hydrophobic surface of the particles. Using acidified sample solutions, acidic and neutral analytes 
would be extracted by hydrophobic interactions, whereas protonated basic analytes would interact 
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via ion exchange mechanisms. Such an approach has been used by, among others, Stolker et al. 
(2004) for SPE of a set of thirteen pharmaceuticals of different classes. Mixed-mode materials with 
reversed-phase and anion exchange properties have been used under slightly basic conditions for 
antibiotics containing carboxylic acid functionality (Benito-Pena et al., 2006).
From the practical point of view, it might be desirable to extract pharmaceuticals from water 
samples without any pH adjustment (Buchberger, 2007). Furthermore, various (neutral) pharma-
ceuticals may exhibit significant hydrophilic properties, which make it difficult to enrich them on 
conventional alkyl-modified silica materials. SPE procedures for extraction of polar compounds 
from aqueous samples are still a big challenge in analytical chemistry. A recent review has summa-
rized new SPE materials that can improve the recoveries for polar analytes (Fontanals et al., 2005). 
These SPE cartridge materials are mainly polymeric sorbents that improve the retention of polar 
compounds either by novel functional groups in the polymeric structure (resulting in a hydrophilic-
hydrophobic balance material) or by considerably increased surface area. Some of these new mate-
rials have turned out to be well suited for multiclass analysis of pharmaceuticals in water samples. 
A number of different SPE stationary phases (Table 16.2) have been evaluated for the extraction of 
the selected pharmaceutical compounds (Hilton and Thomas, 2003; Weigel et al., 2004; Zhang and 
Zhou, 2007). Nowadays, one of the most widely used sorbents is a copolymer of divinylbenzene 
and vinylpyrrolidone, which has been commercialized under the trade name Oasis-HLB by Waters. 
Weigel et al. (2004) demonstrated that this sorbent can simultaneously extract acidic, neutral, and 
basic pharmaceuticals at neutral pH. Multiresidue methods for different classes of pharmaceuti-
cal using Oasis-HLB at neutral pH have also been reported recently by Barceló and co-workers 
(Gomez et al., 2006; Gros et al., 2006). Trenholm et al. (2006) developed a comprehensive method 
for the analysis of fifty-eight potential endocrine-disrupting compounds and pharmaceuticals using 
a single SPE step based on Oasis-HLB. Various other studies can be found describing the successful 
use of Oasis-HLB for pharmaceuticals in water (Petrovic et al., 2006; Zhang and Zhou, 2007). A 
typical multiresidue analysis would include filtration of the seawater, conditioning of the Oasis HLB 
material (between 60 and 500 mg packed into a suitable cartridge) by several milliliters of methanol 
and ultrapure water, application of up to 2 L of sample at a flow rate of approximately 10 ml min–1, 
table 16.2
different types of sPe cartridges being used for Pharmaceutical extraction
cartridge                        description Manufacturer
DSC-C18 Polymerically bonded, octadecyl Supelco
DSC-Si Unbonded acid-washed silica sorbent Supelco
DSC-SCX Aliphatic sulfonic acid, Na+ counterion Supelco
DSC-SAX Quaternary amine, Cl– counterion Supelco
Strata-X-CW Polymeric weak cation Phenomenex
Strata SDB-L Styrene-divinylbenzene polymeric Phenomenex
Chromabond-Easy Bifunctionally modified polystyrene- 
divinylbenzene adsorbent resin
Macherey-Nagel
Chromabond-C18 Hydra Octadecyl-modified silica Macherey-Nagel
Chromabond-Drug Modified silica Macherey-Nagel
Isolute C18 Octadecyl International Sorbent Technology
Isolute C18/ENV+ C18 hydroxylated polystyrene-divinylbenzene International Sorbent Technology
Isolute C8 Octadecyl functionalized silica International Sorbent Technology
Oasis HLB Poly(divinylbenzene-co-N-vinyl-pyrrolidone) Waters
Oasis MCX Poly(divinylbenzene-co-N-vinyl-pyrrolidone, –SO3H) Waters
Varian Bond Elut C18 Irregularly based acid-washed silica Varian
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rinsing the cartridge with several milliliters of ultrapure water to remove salt, drying the SPE mate-
rial by applying a vacuum to remove excess water, elution with approximately 10 ml of methanol 
(it may be necessary to repeat the elution step), evaporation of the extracts under a gentle stream 
of nitrogen (see Section 15.3.4), and reconstitution in 0.5 ml of methanol or a mixture of methanol 
and ultrapure water containing internal standards that are then ready for instrumental analysis. The 
whole analytical procedure is illustrated in Figure 16.3 (Zhang and Zhou, 2007). All the glassware 
used for the extraction is baked at 400°C for 4 hours to eliminate any organic contaminants. All the 
solvents are of distilled-in-glass grade.
Hilton and Thomas (2003) have shown that Strata-X is useful for extracting selected pharma-
ceuticals, after comparing seven types of SPE cartridges. So in a few cases Strata-X (a polydivi-
nylbenzene resin containing piperidone groups manufactured by Phenomenex) has been employed 
for generic SPE procedures (Hilton and Thomas, 2003; Roberts and Bersuder, 2006). Nebot et al. 
(2007) also used Strata-X successfully to determine the concentrations of a range of human phar-
maceuticals in surface and wastewater, but none of the target compounds were above limit of detec-
tion (LOD) in seawater samples collected offshore Scotland. Strata-X may have properties similar 
to those of Oasis-HLB, but at present there is not enough data in the literature to allow this com-
parison to be made.
SPE of pharmaceuticals is often done offline, and is useful for on-site sampling (performing the 
preconcentration step in the field, followed by the elution step in the lab). It is a technique that is 
also well-suited for online procedures and automation in the laboratory. The SPE cartridge can be 
installed in the injection valve instead of the injection loop, and the preconcentrated analytes directly 
Solid Phase Extraction: Oasis HLB
Conditioning: 5 mL MeOH + 5 mL water
Remove Salt: 5 mL Water
Elution: 10 mL MeOH    
Sample Volume
(2 L seawater)  
Filtration: 0.45 µm Glass Fiber Filter  
Internal Standards Added 
Evaporation to Dryness with N2 Gas,
Reconstitution in 0.5 mL MeOH  
Instrumental Analysis
LC-ESI-MS-MS (multiple reaction monitoring)  
FIgure 16.3 The procedures involved in the extraction and analysis of pharmaceuticals in estuarine and 
seawater samples.
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eluted onto the analytical column. An example of this approach is the work of Pozo et al. (2006), 
who determined sixteen antibiotics in surface and groundwater samples. In such a setup, the SPE 
cartridge is generally reused for a series of samples. Contrary to this configuration, fully automated 
SPE procedures with single-use cartridges can be realized by commercially available instrumenta-
tion, such as the SymbiosisTM Environ manufactured by Spark Ltd. This robotic system includes 
an automated cartridge exchange module that transfers the cartridge after the preconcentration step 
into the flow of mobile phase of HPLC (Rodriguez-Mozaz et al., 2007). This approach, which has 
primarily been used with pharmaceutical residues analysis, could be applied in seawater monitor-
ing. There are some significant advantages with the approach (Fatta et al., 2007):
 1. Direct injection of untreated seawater samples
 2. Automatic sample cleanup or analyte enrichment
 3. Elimination of conventional manual sample pretreatment steps
 4. Faster procedures
 5. Methods are less prone to errors, resulting in better reproducibility
 6. Reduction of health risks
 7. Samples can be run unattended (e.g., overnight or over the weekend)
16.4 InstruMental analysIs
The majority of pharmaceuticals lack sufficient volatility and as such are not directly compatible 
with GC analysis (Buchberger, 2007). Various groups of pharmaceuticals can be derivatized to make 
them suited for GC analysis. Although such procedures may be time-consuming and can introduce 
errors due to side reactions during the derivatization, they are still widely in use and well established 
for routine work. The major advantage of GC-MS is the fact that the usual ionization modes such 
as electron impact (EI) or chemical ionization (CI) are generally less affected by the matrix of the 
sample than ionization modes used by, for example, HPLC-MS. Typical derivatization reagents for 
acidic pharmaceuticals include pentafluorobenzylbromide (Reddersen and Heberer, 2003), methyl 
chloromethanoate (Weigel et al., 2004), methanol/BF3 (Verenitch et al., 2006), and tetrabutylam-
monium salts (for derivatization during injection) (Lin et al., 2005). Phenazone-type drugs have 
been derivatized by silylation using N-tert-butyldimethylsiyl-N-methyltrifluoroacetamide (MTB-
STFA) (Zuhlke et al., 2004). Silylation procedures are also commonly used for synthetic estrogens 
(Quintana et al., 2004; Fernandez et al., 2007), although careful selection of the reagent and the 
reaction conditions is necessary to avoid side reactions (Shareef et al., 2006). Derivatization reac-
tions that are useful for sorptive extraction combine with thermal desorption GC.
Generally, the use of GC-MS seems to be a well-established approach for residue analysis of 
pharmaceuticals. Correctly, there is a trend toward tandem MS techniques as the MS component of 
choice for this type of analysis. The advantages of such instruments will be discussed in more detail 
in the context of HPLC-MS.
Despite the indisputable merits of GC procedures for residue analysis of certain classes of phar-
maceuticals, HPLC shows much more universal applicability (Buchberger, 2007). In some cases, 
when just a few analytes of a certain class are to be analyzed, even a simple UV absorbance detec-
tion may be feasible. This has been demonstrated for residues of oxytetracycline in water, which 
can be detected at 360 nm (Himmelsbach and Buchberger, 2005). Fluorescence detection may also 
have some benefits, as shown for the determination of some other compounds, such as anthracycline 
cytostatics and fluoroquinolones (Mahnik et al., 2006; Golet et al., 2001, 2002). Nevertheless, MS 
detection involving atmospheric pressure ionization, such as electrospray ionization (ESI), is nowa-
days state of the art.
Although single-quadrupole instruments have been successfully used, when HPLC-MS proce-
dures started to be developed for pharmaceutical residue analysis (Ahrer et al., 2001), more sophis-
ticated mass analyzers are nowadays commonly employed that allow an unequivocal confirmation 
73060_C016.indd   360 12/31/08   3:15:21 PM
Pharmaceutical Compounds in Estuarine and Coastal Waters 361
of the identities of the analytes. Triple quadrupole (QqQ) MS instruments have become widely used 
with HPLC for environmental analysis. When using a QqQ instrument, false positive results can be 
avoided if the ions of at least two ion-ion transitions are used in combination with at least one ion 
intensity ratio. Several studies have dealt with HPLC-QqQ/MS for multiclass analysis of pharma-
ceuticals (Castiglioni et al., 2005; Rodriguez-Mozaz et al., 2004; Miao et al., 2004; Ternes et al., 
2005; Gomez et al., 2006; Gros et al., 2006; Zhang and Zhou, 2007). Precursor ions and product 
ions used for quantification and confirmation purposes have been compiled for a wide range of 
pharmaceutical compounds (Petrovic et al., 2005).
An example of a typical multipharmaceutical residue analysis by HPLC-QqQ/MS is given 
in Figure 16.4 (Zhang and Zhou, 2007). The LC separation system is equipped with a Waters 
Symmetry C18 column (4.8 mm × 75 mm, particle size 3.5 µm). The mobile phase is made of eluent 
A (0.1% formic acid in ultrapure water), eluent B (acetonitrile), and eluent C (methanol). The flow 
rate of the mobile phase is 0.2 ml min–1. The gradient elution is operated with 10% of eluent B, fol-
lowed by a 25-minute gradient to 80% of eluent B and a 3-minute gradient to 100% of eluent B, and 
then changed to 100% of eluent C within 8 minutes, and hold there for 10 minutes. The system is 
reequilibrated for 10 minutes between runs. Typically the injection volumes are 1 to 10 µl.
A general and well-known problem of HPLC-ESI/MS is ionization suppression due to matrix 
components eluting at the same time as an analyte. On the one hand, ionization suppression effects 
can reduce the sensitivity of the method considerably; on the other hand, special care must be taken 
to achieve reliable quantitation. Ideally, isotopically labeled analytes should be used as internal stan-
dards but are available only in few cases for pharmaceuticals. Otherwise, standard addition methods 
must be applied to obtain correct quantitative data; however, such methods increase the length of 
the analytical procedure considerably. In all cases it makes sense to optimize the efficiency of the 
sample cleanup protocols in order to minimize interferences. New-generation MS instruments in 
some cases allow a dilution of the sample extract before injection into the HPLC system, thereby 
minimizing any matrix effects. Furthermore, other MS detectors such as time of flight (TOF) are 
more selective than QqQ, and hence more suited for samples of highly complex matrices, such as 
wastewater or biological extracts. However, the sensitivity of TOF currently is not as good as QqQ, 
and requires further development.
16.5 analytIcal QualIty controls
To ensure data quality, all the analytical processes should be subject to strict QC procedures to 
determine systematic and random errors. QC measures in relation to estuarine and coastal water 
analysis include the collection of blank water samples derived from laboratory-grade or organic-
free water to determine if sampling procedures, sampling equipment, field conditions, sample 
shipment and storage (field blank), or laboratory procedures (laboratory blank) introduced target 
analytes into environmental samples. The spiked water samples are used to check the precision and 
recoveries. The blank and spiked water samples are typically made by ultrapure water taken from 
a Milli-Q system. Typically, several blank and spiked samples are produced with each set of real 
samples (ten samples for each set). In addition, the random errors involved in sampling are assessed 
by carrying out replicate sampling of water at the same site and the analysis of sample extracts. 
Internal standards (usually the target compounds labeled by stable isotopes such as 13C or 2H) are 
used to compensate for losses involved in the sample extraction and workup, to further character-
ize the method performance. Prior to use, all glassware is rinsed twice with dichloromethane and 
methanol, or is baked at 450°C for 4 hours. All the solvents used are of distilled-in-glass grade. 
All these processes are carried out to minimize the cross-contamination and the loss of analytes 
through adsorption onto the surface of sampling vessels and the extraction apparatus. As seawater 
has a very different matrix to freshwater, more appropriate blanks should be used in the future for 
seawater studies. As an example, synthetic seawater prepared by dissolving appropriate amounts 
of key ionic substances (e.g., NaCl) in ultrapure water at a concentration identical to that in real 
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FIgure 16.4 Chromatograms for the extracted and overlapped MRM of selected pharmaceutical compounds.
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seawater of 35‰ salinity should be a more appropriate matrix for making blank samples and 
spiked recovery samples.
To assess systematic errors, most would use so-called recovery experiments by spiking known 
amounts of each target compound in seawater, followed by extraction and analysis. This gives a 
good indication of how reliable your measurement values are (see Chapter 1). In addition, certified 
reference materials (CRMs) for pharmaceuticals in seawater should be prepared in the future that 
can identify the closeness between a measured value (from an individual laboratory) and a certified 
value (from the supplier). As CRMs are vigorously tested under varying environmental conditions 
by the supplier and independently verified by laboratories worldwide, they become a calibration 
tool for the international community on pharmaceutical research. Ideally, the relative difference 
between measured and certified values should be as small as possible (e.g., ±10%). Such materials 
will ensure that everyone follows the right procedures and generates data of highest quality. In addi-
tion, this practice will ensure monitoring data obtained from any marine samples anywhere can be 
compared against each other, so as to identify hotspots of pharmaceutical pollution, emergence of 
new pharmaceuticals, and temporal variation of pharmaceutical concentrations in the estuarine and 
marine environment.
16.6 IMMunoanalytIcal technIQues
Immunoassays show attractive features for organic trace analysis due to the fact that they require 
little sample pretreatment, exhibit high sensitivity, and are inexpensive in comparison to the instru-
mental analysis described above. A considerable number of immunoassays have been developed and 
used for residue analysis of pesticides in water samples, but immunoassays for pharmaceuticals in 
the aquatic environment are still quite rare. Although test kits for pharmaceuticals are commercially 
available, these kits are in most cases optimized for samples like blood, urine, or food. The appli-
cability to environmental samples has not been investigated in the majority of cases. Deng et al. 
(2003) developed a highly sensitive and specific indirect competitive enzyme-linked immunosorbent 
assay (ELISA) for the determination of diclofenac in water samples. When they applied the assay 
to analysis of diclofenac in tap and surface water as well as wastewater in Austria and Germany, 
they showed that ELISA-derived diclofenac concentrations in wastewater samples were about 25% 
higher than those using GC-MS. The technique should be equally applicable to seawater matrices, 
although the sensitivity and selectivity should be further improved.
16.7 suMMary and PersPectIves
Analysis of emerging pollutants such as pharmaceutically active compounds in the aquatic environ-
ment, including seawater, was reviewed in this chapter. As pharmaceutical compounds are usually 
present at trace levels (e.g., pg L–1 to ng L–1) in complex matrices (e.g., seawater), it is common prac-
tice to develop extraction and analytical methods that can concentrate the target compounds while 
minimizing matrix interference. The analytical procedure involves many interrelated steps, includ-
ing sample pretreatment (e.g., filtration), preconcentration (e.g., SPE), and analysis by advanced 
techniques (e.g., HPLC-MS). Residues of pharmaceuticals have most probably been present in our 
aquatic environment since their application, but only recently have advances in analytical chemis-
try and instrument performance allowed analysis of compounds at low ng L–1 concentrations. The 
development of advanced mass spectrometric detectors for chromatography has made a significant 
contribution to these achievements. The limits of detection of analytical methods may be improved 
even further during the next few years. Residues of pharmaceuticals in aquatic systems are not yet 
included in regular monitoring programs. The high costs of instrumental analysis may be prohibi-
tive to more extended studies. A focus on a limited set of pharmaceuticals that are representative 
in regard to toxic effects may be advantageous (but a final selection of such a set has not yet been 
73060_C016.indd   363 12/31/08   3:15:27 PM
364 Practical Guidelines for the Analysis of Seawater
done). The importance of reliable and inexpensive biosensors may increase in the future, provided 
that they meet the criteria of analytical QC in the same way as traditional techniques do.
In addition, general QC procedures must be followed, including appropriate replicate sampling, 
sample preservation at 4°C, application of isotopically labeled internal standards, suitable blanks, 
satisfactory recovery of the target compounds, and eventually use of certified reference materials 
(either in-house or commercial ones). Although pharmaceutical residues in the environment are a 
major concern and have been widely studied in freshwater systems, the study of their occurrence, 
behavior, and impacts in coastal waters has been quite limited. In addition, the residues of pharma-
ceuticals in aquatic systems are not yet included in the regular monitoring programs of regulatory 
bodies. Further research on emerging pollutants such as pharmaceuticals should be extended to 
coastal and marine ecosystems, including polar regions, where our understanding of pharmaceuti-
cal occurrence and behavior is very limited. The low cost and robustness of passive sampling such 
as POCIS is recommended for routine monitoring of pharmaceuticals and other similar pollutants 
by governmental agencies.
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